Ampyra Lower-Dose Post-Market Study Misses Endpoint
By Catherine Shaffer
Tuesday, August 14, 2012
A post-market study by Acorda Therapeutics Inc. designed to compare a lower 5-mg dose of Ampyra (dalfampridine) to the approved 10-mg dose failed to show any benefit for the 5-mg dose and missed its primary endpoint altogether at both doses. The drug is approved for use in patients with multiple sclerosis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.